Background Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets.
Phoebe A. Tsao +8 more
doaj +1 more source
The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castrationresistant prostate cancer: Post hoc analysis of Korean patients [PDF]
Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial.
Choung-Soo Kim +7 more
doaj +1 more source
Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer [PDF]
Background Enzalutamide and abiraterone may differ in their immunomodulatory effects, and the prednisone coadministered with abiraterone can be immunosuppressive.
Tse, Gary +9 more
core +3 more sources
Dysgeusia is an adverse effect caused by enzalutamide said to affect 1–5% of patients. The reported management strategies include a temporary drug holiday, the prescription of herbal medicine, and changing the timing of enzalutamide intake from morning ...
Takashi Kawahara +3 more
doaj +1 more source
Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity [PDF]
Enzalutamide, a second-generation antiandrogen, is commonly prescribed for the therapy of advanced prostate cancer, but enzalutamide-resistant, lethal, or incurable disease invariably develops. To understand the molecular mechanism(s) behind enzalutamide
Beltran, Himisha +8 more
core +1 more source
Enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: A retrospective Korean multicenter study in a real-world setting [PDF]
Purpose: This study aimed to evaluate the clinical efficacy of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients using real-world data from Korean patients.
Seung Il Jung +18 more
doaj +1 more source
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. [PDF]
Recent advances in understanding the mechanisms underlying the development and progression of castration resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the
Rosario, D.J. +5 more
core +1 more source
Critical role of antioxidant programs in enzalutamide-resistant prostate cancer
Therapy resistance to second-generation androgen receptor (AR) antagonists, such as enzalutamide, is common in patients with advanced prostate cancer (PCa).
Alec Paschalis +27 more
core +1 more source
Patients with castration-resistant prostate cancer (CRPC) often develop drug resistance after treatment with enzalutamide. The goal of our study was to identify the key genes related to enzalutamide resistance in CRPC and to provide new gene targets for ...
Xu Wen +9 more
doaj +1 more source
Molecular determinants for enzalutamide-induced transcription in prostate cancer.
Enzalutamide, a second-generation androgen receptor (AR) antagonist, has demonstrated clinical benefit in men with prostate cancer. However, it only provides a temporary response and modest increase in survival, indicating a rapid evolution of resistance.
Hankey, William +8 more
core +1 more source

